Key facts
- Transcarent’s last known valuation is $2.7B (Apr 2025).
- It has raised $905.0M across 1 recorded rounds; the latest was Later Stage VC ($481.0M) in Apr 2025.
- Notable investors include General Catalyst, Kleiner Perkins, Human Capital, Bridgespan VC, Geodesic Capital — 23 tracked in total.
- Transcarent has filed 1 Form D with the SEC, most recently Apr 2025 ($481.0M sold to 33 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Transcarent
Funding rounds
1 roundsAbout Transcarent
Developer of a consumer-directed health and care platform designed to facilitate improved outcomes and cost-effective decisions. The company leverages a combination of software, technology stack, and data science to empower consumers with information by directly connecting them with an integrated ecosystem of high-value providers and health services, enabling customers to exercise choice and transparency for addressing a broad range of challenges faced in the modern healthcare system.
- Sector
- Healthcare
- HQ
- Denver, CO, United States
- Founded
- 2020
- Employees
- 454
- Website
- transcarent.com/
- Ownership
- Privately Held (backing)
Transcarent doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Transcarent shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Transcarent in its N-PORT filings yet. We sweep new filings monthly.